TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 489751

Group type: EXPERIMENTAL
Intervention: Modelling and feedback from the supervisor (MF)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Feedback from the supervisor (F)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No modelling, no feedback (NMF)
Number of subjects: 24
Study: 31821664

Group type: EXPERIMENTAL
Intervention: Shoulder-umbilical length measurement (experimental group)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Birthweight measurement (control group)
Number of subjects: 110
Study: 31161812

Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Adaptive Support Ventilation (ASV)
Number of subjects: 74
Study: 28079828

Group type: EXPERIMENTAL
Intervention: PHiD-CV primary vaccination and booster dose
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: PHiD-CV
Number of subjects: 283
Study: 26027627

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T
Number of subjects: 5385

Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 5385

Group type: EXPERIMENTAL
Intervention: Growth differentiation factor 15 (GDF-15)
Number of subjects: 5385

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 5385

Group type: EXPERIMENTAL
Intervention: GDF-15
Number of subjects: 5385
Study: 22774850

Group type: EXPERIMENTAL
Intervention: Normal conditions with fast presentation rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal conditions with medium presentation rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal conditions with slow presentation rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Articulatory suppression (AS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rehearsal prevented (slower rates)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overt rehearsal methodology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal encoding conditions
Number of subjects: 0
Study: 21415072

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 2426

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 2426

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2426
Study: 19157352

Group type: EXPERIMENTAL
Intervention: Cobra Perilaryngeal Airway (PLA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Classic Laryngeal Mask Airway (LMA)
Number of subjects: 90
Study: 17915636

Group type: EXPERIMENTAL
Intervention: Carbamazepine immediate release tablet formulation 1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Carbamazepine immediate release tablet formulation 2
Number of subjects: 18

Group type: COMPARATOR
Intervention: In vitro dissolution testing
Number of subjects: 18
Study: 15334791

Group type: EXPERIMENTAL
Intervention: Glimepiride (3+/−1 mg/d)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Metformin (2500+/−500 mg/d)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Glimepiride and Metformin
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 164
Study: 11953015

Group type: EXPERIMENTAL
Intervention: Cytokine-mobilized autologous cancer donors
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cytokine-mobilized normal allogeneic stem-cell donors
Number of subjects: 62

Group type: COMPARATOR
Intervention: Untreated volunteers
Number of subjects: 62
Study: 9924263

Group type: EXPERIMENTAL
Intervention: Detarium flour in stew meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cissus flour in bread meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Detarium bread meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cissus bread meal
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fibre-rich stew meal
Number of subjects: 15
Study: 30340481

Group type: EXPERIMENTAL
Intervention: Health Education and Preventive Equipment Package (HEPEP)
Number of subjects: 645

Group type: COMPARATOR
Intervention: Control group (five-minute lecture)
Number of subjects: 645
Study: 28270389

Group type: EXPERIMENTAL
Intervention: PACE-D web-based tool
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study: 26615342

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no zinc supplementation)
Number of subjects: 100
Study: 23635945

Group type: EXPERIMENTAL
Intervention: Leukoaraiosis presence and severity assessed via brain MRI (T2, FLAIR)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) severity measured by oxygen desaturation index (ODI)
Number of subjects: 183
Study: 19864905

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 2% w/w CPP
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 1,190 mg/kg fluoride as 0.76% SMFP
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo toothpaste without CPP or fluoride
Number of subjects: 150
Study: 17534206

Group type: EXPERIMENTAL
Intervention: Computer-assisted acetabular component insertion (CAOS+ group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Free hand placement (CAOS- group)
Number of subjects: 60
Study: 15155420

Group type: EXPERIMENTAL
Intervention: AAS administration for 8 or 14 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (200 mg/week) for 8 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 35
Study: 11772827

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% isobaric
Number of subjects: 80

Group type: COMPARATOR
Intervention: Racemic bupivacaine 0.5% isobaric
Number of subjects: 80
Study: 11477839

Group type: EXPERIMENTAL
Intervention: Conventional treatment plus concentrated Xuefu Zhuyu Pill (CXZP)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 84
Study: 7642849

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 170

Group type: COMPARATOR
Intervention: Coronary angioplasty
Number of subjects: 170
Study: 2665351

Group type: EXPERIMENTAL
Intervention: PVRV vaccine (new inactivated rabies vaccine grown on Vero cells)
Number of subjects: 144

Group type: COMPARATOR
Intervention: HDCV vaccine (rabies vaccine cultivated on human diploid cells)
Number of subjects: 144
Study: 30598

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (0.5 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Meprobamate (200 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Kymographic recordings
Number of subjects: 31
Study: 31777188

Group type: EXPERIMENTAL
Intervention: Mindfulness (measured by Five Facet Mindfulness Questionnaire)
Number of subjects: 177
Study: 31328807

Group type: EXPERIMENTAL
Intervention: Ivabradine hemisulfate sustained-release tablets 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ivabradine hemisulfate sustained-release tablets 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ivabradine hemisulfate sustained-release tablets 15 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: N-desmethyl ivabradine 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: N-desmethyl ivabradine 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: N-desmethyl ivabradine 15 mg
Number of subjects: 12
Study: 28962727

Group type: EXPERIMENTAL
Intervention: Single-thread TADs
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dual-thread TADs
Number of subjects: 30
Study: 25437153

Group type: EXPERIMENTAL
Intervention: Resilient affective processing (RAP) intervention (n = 12)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Attention-control condition (n = 11)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: RAP intervention (n = 12)
Number of subjects: 33
Study: 23657918

Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus fluoropyrimidines (FL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FL only
Number of subjects: 0
Study: 21966834

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clindamycin
Number of subjects: 0
Study: 19453814

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 17314694

Group type: EXPERIMENTAL
Intervention: Open incubator (n = 23)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Warming bassinet (n = 19)
Number of subjects: 42
Study: 15646226

Group type: EXPERIMENTAL
Intervention: TM-primer applied and dried according to manufacturer's directions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: T30-primer allowed to dry for an additional 30 seconds
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: T60-primer dried for an additional 60 seconds
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: T120-primer dried for an additional 120 seconds
Number of subjects: 12
Study: 11361192

Group type: EXPERIMENTAL
Intervention: Ibuprofen 2,400 mg/day
Number of subjects: 182

Group type: COMPARATOR
Intervention: Acetaminophen 4,000 mg/day
Number of subjects: 182

Group type: COMPARATOR
Intervention: Ibuprofen 1,200 mg/day
Number of subjects: 182
Study: 9743780

Group type: EXPERIMENTAL
Intervention: Individual 1-hour tutorial session on MEDLINE use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 7803332

Group type: EXPERIMENTAL
Intervention: Midazolam (0.15‐0.20 mg/kg)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Thiopentone (4‐6 mg/kg)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 145

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 145
Study: 2460500

Group type: EXPERIMENTAL
Intervention: Abbott enzyme immunoassay for HIV antigen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reverse transcriptase assay (RTA)
Number of subjects: 0
Study: 31097309

Group type: EXPERIMENTAL
Intervention: LAL device (lens awareness logger)
Number of subjects: 40
Study: 27768546

Group type: EXPERIMENTAL
Intervention: Exercise training (10 weeks of supervised moderate intensity exercise at 50% of heart rate reserve)
Number of subjects: 104
Study: 25858333

Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 798

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 798
Study: 23918455

Group type: EXPERIMENTAL
Intervention: Intranasal pulmonary surfactant (PS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated OME
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study: 21403524

Group type: EXPERIMENTAL
Intervention: Quetiapine (50 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 20
Study: 18829151

Group type: EXPERIMENTAL
Intervention: 1 MHz frequency or 1 watt/cm(2) power continuous ultrasound for 5 min, 10 sessions
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sham ultrasound (placebo)
Number of subjects: 67
Study: 18179001

Group type: EXPERIMENTAL
Intervention: Inhalation of 70% isopropyl alcohol
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 0.1 mg granisetron IV
Number of subjects: 57

Group type: COMPARATOR
Intervention: No prophylactic treatment control
Number of subjects: 57
Study: 15337551

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 284
Study: 11135716

Group type: COMPARATOR
Intervention: Infusion of saline for 12 h (Group A: 169 patients)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Infusion of tranexamic acid, 1 mg x kg(‐1) x h(‐1) for 12 h (Group B: 171 patients)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Infusion of tranexamic acid, 2 mg x kg(‐1) x h(‐1) for 12 h (Group C: 170 patients)
Number of subjects: 510
Study: 9821028

Group type: EXPERIMENTAL
Intervention: Single daily dose of two capsules of Cyclo 3 Fort in the morning
Number of subjects: 37

Group type: COMPARATOR
Intervention: Twice daily dose of one capsule of Cyclo 3 Fort morning and noon
Number of subjects: 37
Study: 7978434

Group type: COMPARATOR
Intervention: Placebo PO + tetracaine 12 mg IT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo PO + tetracaine 12 mg IT + fentanyl 10 micrograms IT
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clonidine 200 micrograms PO + tetracaine 12 mg IT
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clonidine 200 micrograms PO + tetracaine 12 mg IT + fentanyl 10 micrograms IT
Number of subjects: 40
Study: 2800973

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 40
Study: 1065740

Group type: EXPERIMENTAL
Intervention: Commercial mouthwash containing cetylpyridinium chloride and domiphen bromide
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Commercial mouthwash containing only cetylpyridinium chloride
Number of subjects: 120

Group type: COMPARATOR
Intervention: Colored flavored water (Control)
Number of subjects: 120
Study: 29202277

Group type: COMPARATOR
Intervention: Clobazam (0.25, 0.50, or 1.0 mg/kg/d) during lead-in; Clobazam up to 2.0 mg/kg/d (maximum 80 mg/d) during OLE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clobazam dosage increase of ≥ 20% during long-term treatment
Number of subjects: 0
Study: 26633145

Group type: EXPERIMENTAL
Intervention: Endotracheal tube (ETT) with premedication (atropine and morphine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA) with premedication (atropine only)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (ETT and LMA)
Number of subjects: 60
Study: 25047862

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 2162

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 2162

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 2162

Group type: COMPARATOR
Intervention: Anti-platelet agents
Number of subjects: 2162

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 2162
Study: 22506793

Group type: EXPERIMENTAL
Intervention: Family-School Success (FSS)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Coping With ADHD Through Relationships and Education (CARE)
Number of subjects: 199
Study: 20422948

Group type: EXPERIMENTAL
Intervention: Itraconazole capsule formulation
Number of subjects: 32
Study: 18043456

Group type: EXPERIMENTAL
Intervention: 3-day therapy with amoxicillin-clavulanate
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 10-day therapy with amoxicillin-clavulanate
Number of subjects: 39
Study: 16045573

Group type: EXPERIMENTAL
Intervention: Acid-suppression duodenal diversion procedures (truncal vagotomy-partial gastrectomy plus Roux-en-Y gastrojejunostomy)
Number of subjects: 73
Study: 12161837

Group type: EXPERIMENTAL
Intervention: Paretic limb during rising from a chair
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nonparetic limb during rising from a chair
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Paretic limb during forward weight-shifting
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nonparetic limb during forward weight-shifting
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All 5 standing tasks
Number of subjects: 15
Study: 10385765

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 g intravenously infused 6 to 12 hours before stenting)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (intravenously infused 6 to 12 hours before stenting)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 8625084

Group type: EXPERIMENTAL
Intervention: Helium-neon laser treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham treatment (control)
Number of subjects: 20
Study: 2205527

Group type: EXPERIMENTAL
Intervention: Ranitidine (400 mg per day for 5 days)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Omeprazole (80 mg per day for 5 days, 120 mg on the 1st day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ranitidine followed by Omeprazole
Number of subjects: 39
Study: 6796711

Group type: EXPERIMENTAL
Intervention: Long-term enteral nutritional support (12 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard parameters of nutritional assessment
Number of subjects: 0
Study: 31050930

Group type: EXPERIMENTAL
Intervention: Desensibilize KF 2%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clinpro XT Varnish
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Photon Lase III (100 mW, 4 J/cm2‐1 J/cm2 each point, 10 sec per point with wavelength of 808 nm)
Number of subjects: 60
Study: 28387846

Group type: EXPERIMENTAL
Intervention: Individualized feedback intervention
Number of subjects: 79

Group type: COMPARATOR
Intervention: Educational session (Control)
Number of subjects: 79
Study: 25889459

Group type: EXPERIMENTAL
Intervention: High-frequency feedback group (HFF group; N=23)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Low-frequency feedback group (LFF group; N=24)
Number of subjects: 47
Study: 22791282

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum for 6 months
Number of subjects: 204

Group type: COMPARATOR
Intervention: Non-xylitol treatment
Number of subjects: 204
Study: 21956721

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (155 U, 31 injections of 5U each, with an additional 40 U as needed)
Number of subjects: 1384

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1384
Study: 19695562

Group type: EXPERIMENTAL
Intervention: Interactive, multimedia online training (OLT)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Two‐day instructor‐led training workshop (ILT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Written treatment manual
Number of subjects: 150
Study: 17146104

Group type: EXPERIMENTAL
Intervention: Gabapentin plus antidepressant
Number of subjects: 118

Group type: COMPARATOR
Intervention: Gabapentin alone
Number of subjects: 118
Study: 15179390

Group type: EXPERIMENTAL
Intervention: Early treatment with either a headgear or a functional appliance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0
Study: 11209119

Group type: EXPERIMENTAL
Intervention: Sequential pulse therapy with itraconazole (200 mg twice daily for 1 week) followed by terbinafine (250 mg twice daily for 1 week)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Terbinafine pulse therapy (3 or 4 pulses of terbinafine)
Number of subjects: 190
Study: 10095974

Group type: EXPERIMENTAL
Intervention: Spermicidal film
Number of subjects: 58

Group type: COMPARATOR
Intervention: No method
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Male latex condom
Number of subjects: 58
Study: 8064960

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Caldwell-Luc operation
Number of subjects: 77
Study: 3310196

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy (ST)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control (vasopressin/balloon tamponade)
Number of subjects: 107
Study: 28701030

Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 314

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 314
Study: 28967523

Group type: EXPERIMENTAL
Intervention: Bovine-human reassortant pentavalent rotavirus vaccine (BRV-PV)
Number of subjects: 7499

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7499
Study: 27313413

Group type: EXPERIMENTAL
Intervention: Vasa Avaleha (VA)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Granules of Vasa Avaleha (GVA)
Number of subjects: 66
Study: 22977265

Group type: EXPERIMENTAL
Intervention: Stimulus Control (SC) training (30-min time- and place-restricted worry period each day for 2 weeks)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Focused Worry (FW) (instructions to not avoid naturally occurring worry for 2 weeks)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Stimulus Control (SC) training
Number of subjects: 53

Group type: COMPARATOR
Intervention: Focused Worry (FW)
Number of subjects: 53
Study: 16320005

Group type: EXPERIMENTAL
Intervention: Seprafilm
Number of subjects: 1701

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 1701

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1701
Study: 12879225

Group type: EXPERIMENTAL
Intervention: Post-operative brace locked in full extension for the first week (Group B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Post-operative brace locked from 0 degrees to 90 degrees (Group A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: KT 1000 arthrometric assessment
Number of subjects: 36
Study: 10600433

Group type: EXPERIMENTAL
Intervention: Parents as sole agents of change (experimental group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Children as sole agents of change (conventional group)
Number of subjects: 60
Study: 7813267

Group type: EXPERIMENTAL
Intervention: Almitrine (A)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 9
Study: 2009851

Group type: EXPERIMENTAL
Intervention: Four units of alcohol (approx. 70 mg alcohol/100 ml blood)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Two units of alcohol (approx. 35 mg alcohol/100 ml blood)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nil units of alcohol (less than 5 mg alcohol/100 ml blood)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no alcohol)
Number of subjects: 8
Study: 7136544

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30085990

Group type: EXPERIMENTAL
Intervention: Psychosocial balance dialogue (PBD) group using Steno Balance Cards
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard care (SC) group
Number of subjects: 92
Study: 27929673

Group type: EXPERIMENTAL
Intervention: Gadoxetate disodium (10 mL diluted 1:1 with saline; injection rate, 2 mL/s)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Gadobenate dimeglumine (0.2 mL/kg; maximum, 20 mL; injection rate, 2 mL/s)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Gadoxetate disodium
Number of subjects: 107